Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claude Schulman

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Clinical Genitourinary Cancer|May 30, 2006
The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panelFred Saad, Celestia S Higano, Oliver Sartor, et al.
The Journal of Sexual Medicine|May 15, 2007
A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunctionGiovanni Corona, Edoardo Mannucci, Luisa Petrone, et al.
European Urology|March 28, 2006
Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunctionGiovanni Corona, Edoardo Mannucci, Claude Schulman, et al.
European Urology|October 24, 2008
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksHendrik Isbarn, Laurent Boccon-Gibod, Peter R Carroll, et al.
World Journal of Urology|March 4, 2020
Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-studyGregor Kadner, Massimo Valerio, Ioannis Giannakis, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Alternating Cystoscopy with Bladder EpiCheck<sup>®</sup> in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison ModelYair Lotan, Georgios Gakis, Matteo Manfredi, et al.
BJU International|November 2, 2018
Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-upFrancesco Porpiglia, Cristian Fiori, Daniele Amparore, et al.
The Journal of Sexual Medicine|April 15, 2010
Endocrine aspects of male sexual dysfunctionsJacques Buvat, Mario Maggi, Louis Gooren, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|September 18, 2004
[Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]Frans Debruyne, Peter Boyle, Fernando Calais da Silva, et al.
Urology|February 25, 2003
Benign prostatic hyperplasia: a progressive disease of aging menMark Emberton, Gerald L Andriole, Jean de la Rosette, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Clinical Genitourinary Cancer|May 30, 2006
The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panelFred Saad, Celestia S Higano, Oliver Sartor, et al.
The Journal of Sexual Medicine|May 15, 2007
A comparison of NCEP-ATPIII and IDF metabolic syndrome definitions with relation to metabolic syndrome-associated sexual dysfunctionGiovanni Corona, Edoardo Mannucci, Luisa Petrone, et al.
European Urology|March 28, 2006
Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunctionGiovanni Corona, Edoardo Mannucci, Claude Schulman, et al.
European Urology|October 24, 2008
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risksHendrik Isbarn, Laurent Boccon-Gibod, Peter R Carroll, et al.
World Journal of Urology|March 4, 2020
Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-studyGregor Kadner, Massimo Valerio, Ioannis Giannakis, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Alternating Cystoscopy with Bladder EpiCheck<sup>®</sup> in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison ModelYair Lotan, Georgios Gakis, Matteo Manfredi, et al.
BJU International|November 2, 2018
Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-upFrancesco Porpiglia, Cristian Fiori, Daniele Amparore, et al.
The Journal of Sexual Medicine|April 15, 2010
Endocrine aspects of male sexual dysfunctionsJacques Buvat, Mario Maggi, Louis Gooren, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|September 18, 2004
[Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]Frans Debruyne, Peter Boyle, Fernando Calais da Silva, et al.
Urology|February 25, 2003
Benign prostatic hyperplasia: a progressive disease of aging menMark Emberton, Gerald L Andriole, Jean de la Rosette, et al.
Pageof 5